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Introduction
Lung transplantation (LTx) is a well-estab-
lished treatment in a number of end-stage 
lung diseases that increases quality of life 
and survival corresponding to a one-, five-, 
and ten-year survival rate of 90 %, 60–70 %, 
and 40–50 %, respectively. Most patients 
die of chronic lung allograft dysfunction 
(CLAD) which affects approximately 50 % of 
all lung transplant recipients after five 
years. Since 2010 growing attention has 
been paid to the phenotyping of CLAD as 
bronchiolitis obliterans syndrome (BOS) 
and restrictive CLAD (rCLAD). BOS is de-
fined as a persistent decline in forced expir-
atory volume in one second (FEV1) of 20 % 
compared to the average of the two best 
post-transplant values, whereas rCLAD is 
defined as a combined decline in FEV1 and 
total lung capacity (TLC) of more than 10 % 
compared to the best post-transplant base-
line values (Sato M et al. J Heart Lung Trans-
plant. 2011;30:735-42). BOS may respond 
well to pharmacological treatment, where-
as there is not yet any documented rCLAD 
treatment. Also, in contrast to BOS, rCLAD 
is associated with pleuroparenchymal fi-
broelastosis (PPFE) on high-resolution com-
puted tomography (HRCT) and has an infe-
rior survival rate compared to BOS (Ver-
leden SE et al. J Heart Lung Transplant. 
2014;33:270-7).
Identification of pleura pathology and fi-
brosis in interstitial lung diseases, such as 
idiopathic PPFE, can be identified using 
lung ultrasound (LUS) in the presence of 
pleural thickening and the so-called inter-
stitial syndrome (IS), which, in accordance 
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with the international evidence-based 
guideline for point-of-care LUS, is defined 
as more than 3 B-lines in more than 2 ante-
rior and/or lateral zones on each hemitho-
rax (Volpicelli G et al. Intensive Care Med. 
2012;38:577-91). As a radiation-free and 
fast procedure which is easily performed 
with minimal discomfort for the patient, 
LUS excels in a clinical setting.
Below we describe LUS findings in a lung 
transplant recipient compatible with PPFE 
findings on an HRCT, which in combination 
with lung physiology was in favor of rCLAD.
Case Description
A male in his mid-fifties with bilateral lung 
transplant due to alfa 1 antitrypsin deficien-
cy with emphysema experienced unantici-
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▶Fig. 1 Course of pre- and post-transplant lung volume values. Black boxes indicate date of lung transplantation (LTx) and follow-up with high-res-
olution computed tomography (HRCT) and lung ultrasound (LUS) due to clinical deterioration. FEV1: Forced expiratory volume in one second. FVC: 
Forced vital capacity. TLC: Total lung capacity. Values for TLC are stated in liters.
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Case Report
pated and increasing dyspnea at his 
post-transplant follow-up at 6 years and 
9 months. A body plethysmography re-
vealed a significant decline in FEV1 and TLC 
compared to previous and stable post- 
transplant values (▶Fig. 1). An HRCT doc-
umented upper lobe pleural and septal 
thickening with fibrotic consolidation com-
patible with the radiological appearance of 
PPFE. On the same day, but following the 
HRCT, the clinical examination was supple-
mented with LUS which identified IS and an 
irregular and thickened pleura line corre-
sponding to the upper lobes as being sug-
gestive of pleuroparenchymal fibrosis. No 
other etiological explanations (e. g., lung 
infection, pneumothorax, pleural effusion) 
a b
▶Fig. 3 a: Axial high-resolution computed tomography (HRCT) image showing pleural thick-
ening as part of pleuroparenchymal fibroelsastosis (PPFE) related restrictive chronic lung allo-
graft dysfunction (rCLAD) corresponding to the left upper lobe. White arrow corresponds 
anatomically to LUS performed in the lateral part of the left upper lobe, so-called zone L3/4, in 
b: LUS clip from the lateral part of the left upper lobe showing confluent parenchymal B-line 
artifacts (B) and a thickened hyperechoic pleura (P).
▶Fig. 2 a: Axial high-resolution computed tomography (HRCT) image showing upper lobe septal 
and pleural thickening with fibrotic consolidation compatible with pleuroparenchymal fibroelasto-
sis (PPFE) related restrictive chronic lung allograft dysfunction (rCLAD). White arrow corresponds 
anatomically to lung ultrasound (LUS) from the anterior part of the right upper lobe, so-called zone 
R1, in b: LUS clip from the anterior part of the right upper lobe. White arrow indicates a pathologi-
cal and fragmented pleural line together with confluent parenchymal B-line artifacts.
a b
for the deterioration in lung function were 
found. In this way the combination of 
radiological imaging (HRCT and LUS) and 
lung physiology facilitated the diagnosis of 
rCLAD (▶ Fig. 2, 3). The described HRCT 
and LUS findings were not identified in the 
lower lobes (▶Fig. 4).
Discussion
To our knowledge, this is the first case re-
port describing the use of LUS in an LTx set-
ting to support a diagnosis of rCLAD.
As this is a case report, we are unable to 
determine whether any of our findings can 
be considered specific of PPFE. Reddy et al. 
dscribed specific HRCT findings in the form 
of pleuroparenchymal thickening in the 
upper lobes (Reddy TL et al. Eur Resp J 2012: 
40;377-85). Since pleuroparenchymal 
thickening can be identified using HRCT, 
the same findings might be extrapolated 
when assessing patients with LUS. Howev-
er, a major limitation is that LUS cannot be 
used to assess the underlying aerated lung 
tissue. Possible pitfalls could therefore be 
other conditions with pleural thickening 
predominantly affecting the upper lobes 
(e. g., chronic pulmonary aspergillosis 
(CPA), pulmonary sarcoidosis stage IV, and 
chronic hypersensitivity pneumonitis 
(cHP)). Nevertheless, when assessing the 
thickened pleura in the upper lobes, some 
signs may possibly be used to differentiate 
PPFE from other conditions. CPA may cause 
apical pleural thickening to the same extent 
as PPFE, but as opposed to PPFE the pleural 
thickening is relatively homogeneous. 
When CPA is assessed using LUS, the thick-
ened pleura may thus appear homogene-
ous with fragmentation being less pro-
nounced. In pulmonary sarcoidosis stage IV 
and cHP, the pleura may appear thickened 
and fragmented in the upper lobes. How-
ever, based on the study by Reddy et al., we 
expect the extent of pleural thickening to 
be more severe in PPFE than in sarcoidosis 
stage IV and cHP. In studies assessing the 
use of LUS in interstitial lung diseases, the 
predominant findings are B-lines and a 
thickened and fragmented pleura line (Re-
issig A et al. Respiration 2014;87:179-89). 
The fragmented pleura line most often ap-
pears hyperechoic and not hypoechoic as 
was the case in the presented case. As such, 
LUS findings in the form of relatively marked 
pleural thickening and concomitant frag-
mentation in the upper lobes may be spe-
cific LUS findings compatible with PPFE.
HRCT is a mandatory radiological mo-
dality in the examination of CLAD in com-
bination with lung physiology and some-
times  invasive diagnostic procedures. 
However, based on the above- mentioned 
reflections, LUS may be considered as an 
alternative add-on diagnostic modality to 
HRCT in order to support the distinction 
and phenotyping of CLAD subtypes as BOS 
and rCLAD. Due to the inferior prognosis 
of rCLAD, a potential association between 
HRCT verified PPFE and LUS findings sug-
gestive of PPFE in rCLAD patients is also of 
prognostic interest, and furthermore, sup-
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ports the use of LUS as a potential monitor-
ing tool for rCLAD (i. e.,  PPFE) progression.
In this case the supplemental LUS find-
ings did not influence the clinical manage-
ment but did provide the clinician with 
more specific knowledge regarding a worse 
prognosis than BOS. Such knowledge may 
ultimately provide better timing of overall 
management including long-term oxygen 
therapy, experimental treatments, re-trans-
plantation, and palliation.
As there is no evidence on this topic, 
prospective studies validating LUS with 
HRCT findings as the gold standard in a se-
ries of cases with CLAD are warranted to 
yield more information about the role of 
LUS in a clinical context.
a b
▶Fig. 4 a: Sagittal high-resolution computed tomography (HRCT) image of the right lung and 
pleura showing pleural thickening and upper lobe fibrotic consolidation as part of pleuroparen-
chymal fibroelastosis (PPFE) related restrictive chronic lung allograft dysfunction (rCLAD). 
White arrow corresponds anatomically to LUS performed at the basal and posterior part of the 
right lower lobe, so-called zone R5, in b: LUS clip from the posterior and basal part of the right 
lower lobe showing no B-line artifacts (B) and a less thickened pleura without fragmentation 
(P). Lvr indicates the liver in both Figures A and B.
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